ArQule, Inc. to Present at the CIBC and Rodman & Renshaw Healthcare Conferences on November 5-6, 2007.

Rodman & Renshaw live web cast scheduled for November 5, 10:35 p.m. eastern time; CIBC live web cast scheduled for November 6, 8:35 a.m. eastern time

WOBURN, Mass. -- ArQule, Inc. (Nasdaq: ARQL) today announced that it will present at the Acumen BioFin / Rodman & Renshaw 9th Annual Healthcare Conference at the New York Palace Hotel on Monday, November 5, 2007 at 10:35 a.m. eastern time. ArQule will also present at the CIBC World Markets 18th Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York on Tuesday, November 6, 2007 at 8:35 a.m. eastern time.

ArQule's presentations will be webcast live and can be accessed through the investor relations section of the Company's website, www.ArQule.com.

About ArQule

ArQule, Inc. is a biotechnology company engaged in the research and development of next-generation, small-molecule cancer therapeutics. The Company's targeted, broad-spectrum products and research programs are designed to affect key biological processes that are central to cancer. ArQule's lead clinical-stage products have been generated from two scientific platforms: Cancer Survival Protein modulation and Activated Checkpoint Therapy([R]) (ACT). The Cancer Survival Protein modulation platform has generated a clinical-stage product designed to inhibit a molecule known as c-Met, which plays multiple roles in cancer cell growth, survival, invasion, angiogenesis and metastasis. The ACT platform is designed to kill cancer cells selectively while sparing normal cells through direct activation of DNA damage response/checkpoint pathways. The Company's lead ACT program, based on the E2F-1 pathway, is partnered with Roche. For more information, please visit www.arqule.com.